Skip to main content

Elucidation of tumour cell plasticity mechanisms associated to treatment in metastatic prostate cancer

Project description

Predictive biomarkers in the treatment of metastatic prostate cancer

Prostate cancer (PC) is among the top five deadliest cancers worldwide. In recent years, several new options for the treatment of metastatic PC have been approved, providing additional therapeutic choices. However, not all patients respond to the treatments, and most of them eventually develop resistance. There is an urgent need for predictive biomarkers to assist in optimal treatment selection, allowing timely changes in the treatment of non-responding patients. The EU-funded PDX-PC project aims to elucidate the molecular mechanisms responsible for tumour cell plasticity associated with treatment response in cases of metastatic PC. Researchers will employ patient-derived xenografts as in vivo models and genomics analysis to understand the molecular evolution of the disease, which will allow them to design more specific and individualised treatments in the future.

Coordinator

FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Net EU contribution
€ 166 202,88
Address
Carrer Rossello 149
08036 Barcelona
Spain

See on map

Region
Este Cataluña Barcelona
Activity type
Research Organisations
Other funding
€ 0,00

Partners (1)

Partner

Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.

MONASH UNIVERSITY
Australia
Net EU contribution
€ 0,00
Other funding
€ 85 736,64